EXEL vs IOVA
Exelixis vs Iovance Biotherapeutics, Inc. — AI-powered side-by-side comparison
VS
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
| Metric | EXEL | IOVA |
|---|
| AI Score |
67
|
67
|
| Price |
$51.30
|
$6.49
|
| P/E Ratio |
15.60×
|
-9.27×
|
| ROE |
36.2%
|
-56.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
116.3%
|
| Debt / Equity |
0.09×
|
0.06×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
41.0
|
79.2
|
| Beta |
0.422
|
0.701
|
| Expected Upside |
+8.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for EXEL versus IOVA.
The committee scores are tied.
EXEL and IOVA both score 67/100.
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical